PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 134 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $18,000 | -64.7% | 2,692 | -67.2% | 0.00% | – |
| Q4 2020 | $51,000 | +168.4% | 8,215 | +134.8% | 0.00% | – |
| Q3 2020 | $19,000 | -24.0% | 3,498 | -25.5% | 0.00% | – |
| Q2 2020 | $25,000 | +212.5% | 4,697 | +72.9% | 0.00% | – |
| Q1 2020 | $8,000 | -71.4% | 2,716 | -61.0% | 0.00% | – |
| Q4 2019 | $28,000 | -22.2% | 6,973 | -16.8% | 0.00% | – |
| Q3 2019 | $36,000 | +16.1% | 8,381 | +7.2% | 0.00% | – |
| Q2 2019 | $31,000 | +342.9% | 7,816 | +503.1% | 0.00% | – |
| Q1 2019 | $7,000 | -12.5% | 1,296 | -14.9% | 0.00% | – |
| Q4 2018 | $8,000 | +166.7% | 1,523 | +326.6% | 0.00% | – |
| Q3 2018 | $3,000 | +50.0% | 357 | +59.4% | 0.00% | – |
| Q2 2018 | $2,000 | -98.5% | 224 | -97.9% | 0.00% | – |
| Q1 2018 | $136,000 | +13500.0% | 10,424 | +15936.9% | 0.00% | – |
| Q4 2017 | $1,000 | -50.0% | 65 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 65 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | +100.0% | 65 | 0.0% | 0.00% | – |
| Q1 2017 | $1,000 | – | 65 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |